What nanomedicine in the clinic right now really forms nanoparticles?

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 6, Issue 2, 2014, Pages 125-135

  Svenson, Sonke ^a  

^a Drug Delivery Solutions LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGREGATION BEHAVIOR; CLINICAL EVALUATION; CLINICAL TRANSLATION; PHARMACOKINETIC DATA; POLYMERIC MICELLE; STRUCTURAL DIFFERENCES; STRUCTURE-RELATED; THERAPEUTIC TOOLS;

COMMERCE; LIPOSOMES; MICELLES; NANOPARTICLES; RESEARCH;

MEDICAL NANOTECHNOLOGY;

CAMPTOTHECIN; COPOLYMER; LIPOSOME; NANOCARRIER; NANOPARTICLE; PACLITAXEL;

ARTICLE; CLINICAL EVALUATION; MICELLE; NANOMEDICINE; PRIORITY JOURNAL;

ALBUMINS; CAMPTOTHECIN; DRUG CARRIERS; HUMANS; LIPOSOMES; MICELLES; NANOMEDICINE; NANOPARTICLES; PACLITAXEL; POLYMERS;

EID: 84893737274     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1257     Document Type: Article

References (48)

1. Caruso F, Hyeon T, Rotello VM. Nanomedicine. Chem Rev Soc 2012, 41:2537-2538.
2. Svenson S. Clinical translation of nanomedicines. Curr Opin Solid State Mater Sci 2012, 16:287-294.
3. Svenson S, Prud'homme RK, eds. Multifunctional Nanoparticles for Drug Delivery Applications. Nanostructure Science and Technology Series. New York, Dordrecht, Heidelberg, London: Springer; 2012.
4. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
5. Bharali DJ, Mousa SA. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Ther 2010, 128:324-335.
6. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
7. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharmaceutics 2011, 8:2104-2141.
8. Li Y, Wang J, Wientjes MG, Au JLS. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev 2012, 64:29-39.
9. Gu F, Zhang J, Teply BA, Mann N, Wang A, Radovic-Moreno AF, Langer R, Farokhzad OC. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A 2008, 105:2586-2591.
10. Kwon IK, Lee SC, Han B, Park K. Analysis on the current status of targeted drug delivery to tumors. J Control Release 2012, 164:108-114.
11. http://www.starpharma.com/vivagel/vivagel_clinical_trials. (Accessed June 15, 2013).
12. Cohen-Sela E, Chorny M, Koroukhov N, Danenberg HD, Golomb G. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J Control Release 2009, 133:90-95.
13. Anton N, Vandamme TF. Nano-emulsions and micro-emulsions: clarifications of the critical differences. Pharm Res 2011, 28:978-985.
14. Lawrence MJ, Rees DG. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2012, 64(Suppl):175-193.
15. Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm 2010, 385:113-142.
16. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160.
17. Al-Jamal WT, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res 2011, 44:1094-1104.
18. Contreras FX, Sánchez-Magraner L, Alonso A, Goñi FM. Transbilayer (flip-flop) lipid motion and lipid scrambling in membranes. FEBS Lett 2010, 584:1779-1786.
19. Meng F, Zhong Z, Feijen J. Stimuli-responsive polymersomes for programmed drug delivery. Biomacromolecules 2009, 10:196-209.
20. Shum HC, Zhao YJ, Kim SH, Weitz DA. Multicompartment polymersomes from double emulsions. Angw Chem Int Ed 2011, 50:1648-1651.
21. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 2010, 6:714-729.
22. Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, Terada Y, Kano MR, Miyazono K, Uesaka M, et al. Accumulation of sub-100nm micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011, 6:815-823.
23. Hu CM, Zhang L. Therapeutic nanoparticles to combat cancer drug resistance. Curr Drug Metab 2009, 10:836-841.
24. Beija M, Salvayre R, Lauth-de Viguerie N, Marty JD. Colloidal systems for drug delivery: from design to therapy. Trends Biotechnol 2012, 30:485-496.
25. Fleige E, Quadir MA, Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv Drug Deliv Rev 2012, 64:866-884.
26. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumor delivery by EPR effect. Adv Drug Deliv Rev 2011, 63:170-183.
27. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, Ahmad I. Development and characterization of a novel cremophor® EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 2005, 59:177-187.
28. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed 2012, 7:49-60.
29. http://www.cesar.or.at/download/text/1790/33.%20Abstract%20Kl%C3%B6pper.pdf (Accessed July 12, 2013).
30. Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, et al. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during Phase I development of liposome-entrapped paclitaxel. Clin Cancer Res 2008, 14:5856-5863.
31. Koudelka S, Turanek J. Liposomal paclitaxel formulations. J Control Release 2012, 163:322-334.
32. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ. Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004, 10:3708-3716.
33. Lim WT, Tan EH, Toh CK, Hee SW, Leong SS, Ang PCS, Wong NS, Chowbay B. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors. Ann Oncol 2010, 21:382-388.
34. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumor activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 2005, 92:1240-1246.
35. Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H, Muro K, Yamada Y, Okusaka T, Shirao K, et al. A Phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer 2007, 97:170-176.
36. Chin K, Kato K, Yoshikawa T, Yamaguchi K, Esaki T, Tsuji Y, Sakai K, Kimura M, Ikeda R, Matsumura Y. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle as second-line treatment for advanced or recurrent gastric cancer. J Clin Oncol 2010, 28:4041(2010 ASCO Annual Meeting Proceedings).
37. Yang D, Yu L, Van S. Clinically relevant anticancer polymer paclitaxel therapeutics. Cancers 2011, 3:17-42.
38. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 2007, 24:1029-1046.
39. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of Taxol. Cancer Res 1987, 47:2486-2493.
40. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane®ABI-007) in the treatment of breast cancer. Int J Nanomed 2009, 4:99-105.
41. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803.
42. Sparreboom A, Scripture CD, Trieu V, Williams PJ, de Rab T, Yang A, Beals B, Figg WD, Hawkins M, Desai N. Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005, 11:4136-4143.
43. Elsadek B, Kratz F. Impact of albumin on drug delivery - New Applications on the horizon. J Control Release 2012, 157:4-28.
44. Li QY, Zu YG, Shi RZ, Yao LP. Review camptothecin: current perspectives. Curr Med Chem 2006, 13:2021-2039.
45. Svenson S, Wolfgang M, Hwang J, Ryan J, Eliasof S. Preclinical to clinical development of the novel camptothecin nanopharmaceuticalCRLX101. J Control Release 2011, 153:49-55.
46. Yurkovetskiy AV, Fram RJ. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. Adv Drug Deliv Rev 2009, 61:1193-1202.
47. Gaur S, Chen L, Yen T, Wang Y, Zhou B, Davis ME, Yen Y. Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. Nanomedicine 2012, 8:721-730.
48. Svenson S, Kirste B, Fuhrhop JH. A CPMAS 13-C NMR study of molecular conformations and disorder of N-octylhexonamides in microcrystals and supramolecular assemblies. J Am Chem Soc 1994, 116:11969-11975.